SG Americas Securities LLC bought a new stake in RxSight, Inc. (NASDAQ:RXST - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 36,267 shares of the company's stock, valued at approximately $916,000. SG Americas Securities LLC owned approximately 0.09% of RxSight as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of RxSight by 4.2% in the fourth quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company's stock valued at $81,946,000 after acquiring an additional 96,464 shares in the last quarter. Bank of America Corp DE boosted its holdings in RxSight by 23.7% during the fourth quarter. Bank of America Corp DE now owns 2,159,923 shares of the company's stock worth $74,258,000 after buying an additional 413,737 shares in the last quarter. Artisan Partners Limited Partnership boosted its holdings in RxSight by 32.6% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,551,620 shares of the company's stock worth $53,345,000 after buying an additional 381,389 shares in the last quarter. Geode Capital Management LLC boosted its holdings in RxSight by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 830,758 shares of the company's stock worth $28,568,000 after buying an additional 13,641 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in RxSight by 1.6% during the fourth quarter. Deutsche Bank AG now owns 657,224 shares of the company's stock worth $22,595,000 after buying an additional 10,634 shares in the last quarter. Hedge funds and other institutional investors own 78.78% of the company's stock.
RxSight Stock Performance
RXST traded down $0.26 during midday trading on Friday, reaching $13.61. 653,062 shares of the company's stock were exchanged, compared to its average volume of 708,226. The business's 50-day moving average price is $14.75 and its 200 day moving average price is $24.72. RxSight, Inc. has a 1-year low of $12.53 and a 1-year high of $60.81.
RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.03). The company had revenue of $37.90 million during the quarter, compared to analysts' expectations of $38.74 million. RxSight had a negative net margin of 17.90% and a negative return on equity of 9.54%. The firm's quarterly revenue was up 28.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.25) earnings per share. As a group, research analysts predict that RxSight, Inc. will post -0.7 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of research firms recently commented on RXST. JPMorgan Chase & Co. reissued an "underweight" rating and set a $17.00 price objective (down previously from $40.00) on shares of RxSight in a report on Friday, April 4th. Bank of America reissued an "underperform" rating and set a $22.00 price objective (down previously from $36.00) on shares of RxSight in a report on Thursday, April 3rd. Needham & Company LLC reissued a "buy" rating and set a $43.00 price objective on shares of RxSight in a report on Thursday, April 3rd. Stifel Nicolaus decreased their price objective on shares of RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Finally, UBS Group downgraded shares of RxSight from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $45.00 to $16.00 in a report on Wednesday, April 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $37.90.
Check Out Our Latest Research Report on RxSight
About RxSight
(
Free Report)
RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.
Recommended Stories
Before you consider RxSight, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list.
While RxSight currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
